Identification

Name
Olsalazine
Accession Number
DB01250
Type
Small Molecule
Groups
Approved
Description

Olsalazine is an anti-inflammatory drug used in the treatment of Inflammatory Bowel Disease and Ulcerative Colitis. Olsalazine is a derivative of salicylic acid. Inactive by itself (it is a prodrug), it is converted by the bacteria in the colon to mesalamine. Mesalamine works as an anti-inflammatory agent in treating inflammatory diseases of the intestines.

Structure
Thumb
Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Olsalazine sodiumY7JEW0XG7I6054-98-4QQWFSVYVHLECFP-XBPUGJBTSA-L
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DipentumCapsule, gelatin coated250 mg/1OralCarilion Materials Management1990-07-31Not applicableUs
DipentumCapsule250 mgOralAtnahs Pharma Uk Limited1995-12-31Not applicableCanada
DipentumCapsule, gelatin coated250 mg/1OralCarilion Materials Management2015-05-15Not applicableUs
DipentumCapsule, gelatin coated250 mg/1OralAlaven Pharmaceutical1990-07-312018-04-05Us
DipentumCapsule, gelatin coated250 mg/1OralMeda Pharmaceuticals Ltd2015-05-15Not applicableUs
International/Other Brands
Dipentum
Categories
UNII
ULS5I8J03O
CAS number
15722-48-2
Weight
Average: 302.239
Monoisotopic: 302.053886062
Chemical Formula
C14H10N2O6
InChI Key
QQBDLJCYGRGAKP-FOCLMDBBSA-N
InChI
InChI=1S/C14H10N2O6/c17-11-3-1-7(5-9(11)13(19)20)15-16-8-2-4-12(18)10(6-8)14(21)22/h1-6,17-18H,(H,19,20)(H,21,22)/b16-15+
IUPAC Name
5-[(E)-2-(3-carboxy-4-hydroxyphenyl)diazen-1-yl]-2-hydroxybenzoic acid
SMILES
OC(=O)C1=CC(=CC=C1O)\N=N\C1=CC=C(O)C(=C1)C(O)=O

Pharmacology

Indication

For the treatment of Inflammatory Bowel Disease and Ulcerative Colitis.

Associated Conditions
Pharmacodynamics

Olsalazine is an anti-inflammatory drug used in the treatment of Inflammatory Bowel Disease and Ulcerative Colitis. Olsalazine reduces the bowel inflammation, diarrhea (stool frequency), rectal bleeding, and abdominal pain. Like Balsalazide, Olsalazine is believed to deliver Mesalazine, or 5-aminosalicylic acid (5-ASA), past the small intestine, directly to the large intestine, which is that active site of disease in ulcerative colitis.

Mechanism of action

Orally administered olsalazine is converted to mesalamine which is thought to be the therapeutically active agent in the treatment of ulcerative colitis. The mechanism of action of mesalamine (and sulfasalazine) is unknown, but appears to be topical rather than systemic. Mucosal production of arachidonic acid (AA) metabolites, both through the cyclooxygenase pathways, i.e., prostanoids, and through the lipoxygenase pathways, i.e., leukotrienes (LTs) and hydroxyelcosatetraenoic acids (HETEs) is increased in patients with chronic inflammatory bowel disease, and it is possible that mesalamine diminishes inflammation by blocking cyclooxygenase and inhibiting prostaglandin (PG) production in the colon.

TargetActionsOrganism
AThiopurine S-methyltransferase
inhibitor
Human
AInterferon gammaNot AvailableHuman
Absorption

After oral administration, olsalazine, has limited systemic bioavailability. 98-99% of the dose is converted to mesalamine (5-ASA) in the colon, which is absorbed slowly resulting in very high local concentrations in the colon.

Volume of distribution
Not Available
Protein binding

Olsalazine and olsalazine-S are more than 99% bound to plasma proteins. Mesalamine (5-ASA) is 74% bound to plasma proteins.

Metabolism

Most (98 to 99%) of an oral dose is rapidly converted into two molecules of 5-aminosalicylic acid (5-ASA) by colonic bacteria and the low prevailing redox potential found in this environment. The conversion of olsalazine to mesalamine in the colon is similar to that of sulfasalazine, which is converted into sulfapyridine and mesalamine. Approximately 0.1% of an oral dose of olsalazine is metabolized in the liver to olsalazine-O-sulfate (olsalazine-S)

Route of elimination

Approximately 0.1% of an oral dose of olsalazine is metabolized in the liver to olsalazine-O-sulfate (olsalazine-S).The remaining 5-ASA is partially acetylated and is excreted in the feces.

Half life

Olsalazine has an elimination half-life of 0.9 hours, however, olsalazine-S has a half-life of 7 days.

Clearance
Not Available
Toxicity

Maximum single oral doses of 5g/kg in mice and rats and 2 g/kg in dogs were not lethal.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limonene(4R)-limonene may increase the nephrotoxic activities of Olsalazine.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Olsalazine is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Olsalazine is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Olsalazine is combined with 5-androstenedione.Experimental, Illicit
AbciximabOlsalazine may increase the anticoagulant activities of Abciximab.Approved
AcarboseOlsalazine may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololOlsalazine may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Olsalazine is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Olsalazine is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolOlsalazine may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AcetaminophenThe risk or severity of adverse effects can be increased when Olsalazine is combined with Acetaminophen.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Olsalazine is combined with Acetazolamide.Approved, Vet Approved
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Olsalazine.Approved
AcetyldigoxinThe serum concentration of Acetyldigoxin can be decreased when it is combined with Olsalazine.Experimental
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Olsalazine is combined with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneAdapalene may increase the nephrotoxic activities of Olsalazine.Approved
AlbiglutideOlsalazine may increase the hypoglycemic activities of Albiglutide.Approved
AlclofenacAlclofenac may increase the nephrotoxic activities of Olsalazine.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Aldosterone.Experimental, Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Olsalazine is combined with Alendronic acid.Approved
AliskirenOlsalazine may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenAlminoprofen may increase the nephrotoxic activities of Olsalazine.Experimental
AlogliptinOlsalazine may increase the hypoglycemic activities of Alogliptin.Approved
AloxiprinThe risk or severity of adverse effects can be increased when Olsalazine is combined with Aloxiprin.Experimental
AlprenololOlsalazine may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Olsalazine.Approved, Investigational
AlteplaseThe risk or severity of adverse effects can be increased when Olsalazine is combined with Alteplase.Approved
AmcinonideThe risk or severity of adverse effects can be increased when Olsalazine is combined with Amcinonide.Approved
AmikacinOlsalazine may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Investigational, Vet Approved
AmilorideOlsalazine may decrease the antihypertensive activities of Amiloride.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Olsalazine is combined with Aminosalicylic Acid.Approved
AmiodaroneOlsalazine may decrease the antihypertensive activities of Amiodarone.Approved, Investigational
Ammonium chlorideThe serum concentration of Olsalazine can be increased when it is combined with Ammonium chloride.Approved, Investigational, Vet Approved
AnagrelideThe risk or severity of adverse effects can be increased when Anagrelide is combined with Olsalazine.Approved
AncrodOlsalazine may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideAndrographolide may increase the nephrotoxic activities of Olsalazine.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Olsalazine is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Olsalazine is combined with anecortave acetate.Investigational
AnisodamineAnisodamine may increase the nephrotoxic activities of Olsalazine.Investigational
AnistreplaseThe risk or severity of adverse effects can be increased when Olsalazine is combined with Anistreplase.Approved
AntipyrineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Antipyrine.Approved, Investigational
Antithrombin III humanOlsalazine may increase the anticoagulant activities of Antithrombin III human.Approved
AntrafenineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Antrafenine.Approved
ApixabanOlsalazine may increase the anticoagulant activities of Apixaban.Approved
ApocyninApocynin may increase the nephrotoxic activities of Olsalazine.Investigational
ApramycinOlsalazine may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastApremilast may increase the nephrotoxic activities of Olsalazine.Approved, Investigational
ArbekacinOlsalazine may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinOlsalazine may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanOlsalazine may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololOlsalazine may decrease the antihypertensive activities of Arotinolol.Investigational
AsenapineOlsalazine may decrease the antihypertensive activities of Asenapine.Approved
AstaxanthinThe risk or severity of adverse effects can be increased when Olsalazine is combined with Astaxanthin.Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Atamestane.Investigational
AtenololOlsalazine may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneAzapropazone may increase the nephrotoxic activities of Olsalazine.Withdrawn
AzathioprineThe metabolism of Azathioprine can be decreased when combined with Olsalazine.Approved
AzelastineAzelastine may increase the nephrotoxic activities of Olsalazine.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Olsalazine is combined with Azficel-T.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Olsalazine.Approved, Investigational
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Olsalazine.Investigational
BalsalazideThe risk or severity of adverse effects can be increased when Olsalazine is combined with Balsalazide.Approved, Investigational
BatroxobinThe risk or severity of adverse effects can be increased when Olsalazine is combined with Batroxobin.Experimental
BecaplerminOlsalazine may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Olsalazine is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololOlsalazine may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinOlsalazine may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BemiparinThe risk or severity of adverse effects can be increased when Olsalazine is combined with Bemiparin.Approved, Investigational
BenazeprilThe risk or severity of adverse effects can be increased when Olsalazine is combined with Benazepril.Approved, Investigational
BendazacBendazac may increase the nephrotoxic activities of Olsalazine.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Olsalazine.Approved
BenorilateBenorilate may increase the nephrotoxic activities of Olsalazine.Experimental
BenoxaprofenBenoxaprofen may increase the nephrotoxic activities of Olsalazine.Withdrawn
BenzthiazideThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Olsalazine.Approved
BenzydamineBenzydamine may increase the nephrotoxic activities of Olsalazine.Approved
BeraprostThe risk or severity of adverse effects can be increased when Beraprost is combined with Olsalazine.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Betamethasone.Approved, Vet Approved
BetaxololOlsalazine may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Olsalazine.Approved, Investigational
BevantololOlsalazine may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumBevonium may increase the nephrotoxic activities of Olsalazine.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Olsalazine.Approved, Investigational
BisoprololOlsalazine may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinOlsalazine may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololOlsalazine may decrease the antihypertensive activities of Bopindolol.Approved
BrinaseThe risk or severity of adverse effects can be increased when Olsalazine is combined with Brinase.Experimental
BrinzolamideThe risk or severity of adverse effects can be increased when Olsalazine is combined with Brinzolamide.Approved
BromfenacThe risk or severity of adverse effects can be increased when Olsalazine is combined with Bromfenac.Approved
BromocriptineOlsalazine may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
BucillamineBucillamine may increase the nephrotoxic activities of Olsalazine.Investigational
BucindololOlsalazine may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Olsalazine is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Olsalazine is combined with Bufexamac.Approved, Experimental
BuflomedilThe risk or severity of adverse effects can be increased when Buflomedil is combined with Olsalazine.Experimental
BufuralolOlsalazine may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneBumadizone may increase the nephrotoxic activities of Olsalazine.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Olsalazine.Approved
BupranololOlsalazine may decrease the antihypertensive activities of Bupranolol.Approved
ButylphthalideThe risk or severity of adverse effects can be increased when Butylphthalide is combined with Olsalazine.Investigational
CanagliflozinOlsalazine may increase the hypoglycemic activities of Canagliflozin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Olsalazine.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Olsalazine.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Olsalazine is combined with Candoxatril.Experimental
CangrelorThe risk or severity of adverse effects can be increased when Cangrelor is combined with Olsalazine.Approved
CaplacizumabThe risk or severity of adverse effects can be increased when Olsalazine is combined with Caplacizumab.Investigational
CapsaicinThe risk or severity of adverse effects can be increased when Olsalazine is combined with Capsaicin.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Olsalazine is combined with Captopril.Approved
Carbaspirin calciumCarbaspirin calcium may increase the nephrotoxic activities of Olsalazine.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Olsalazine.Approved
CarprofenThe risk or severity of adverse effects can be increased when Olsalazine is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololOlsalazine may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolOlsalazine may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineCastanospermine may increase the nephrotoxic activities of Olsalazine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Olsalazine is combined with Celecoxib.Approved, Investigational
CeliprololOlsalazine may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinOlsalazine may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineChloroquine may increase the nephrotoxic activities of Olsalazine.Approved, Investigational, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Olsalazine.Approved, Vet Approved
ChlorphenesinThe risk or severity of adverse effects can be increased when Olsalazine is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorpropamideOlsalazine may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Olsalazine.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Olsalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Olsalazine is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Olsalazine is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Olsalazine is combined with Cilazapril.Approved
CilostazolThe risk or severity of adverse effects can be increased when Cilostazol is combined with Olsalazine.Approved, Investigational
CimicoxibThe risk or severity of adverse effects can be increased when Olsalazine is combined with Cimicoxib.Investigational
CinoxacinOlsalazine may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinOlsalazine may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
CisplatinThe risk or severity of adverse effects can be increased when Olsalazine is combined with Cisplatin.Approved
Citric AcidOlsalazine may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Olsalazine is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Olsalazine is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Olsalazine is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinClonixin may increase the nephrotoxic activities of Olsalazine.Approved
ClopidogrelThe risk or severity of adverse effects can be increased when Clopidogrel is combined with Olsalazine.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Olsalazine.Vet Approved
CloranololOlsalazine may decrease the antihypertensive activities of Cloranolol.Experimental
CloricromenThe risk or severity of adverse effects can be increased when Cloricromen is combined with Olsalazine.Experimental
ClorindioneOlsalazine may increase the anticoagulant activities of Clorindione.Experimental
ColesevelamColesevelam can cause a decrease in the absorption of Olsalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Olsalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Olsalazine is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Olsalazine is combined with Cortisone acetate.Approved, Investigational
CurcuminCurcumin may increase the nephrotoxic activities of Olsalazine.Approved, Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Olsalazine.Experimental
CyclosporineOlsalazine may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
CymarinThe serum concentration of Cymarin can be decreased when it is combined with Olsalazine.Experimental
Dabigatran etexilateOlsalazine may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinOlsalazine may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidOlsalazine may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DapagliflozinOlsalazine may increase the hypoglycemic activities of Dapagliflozin.Approved
DarexabanOlsalazine may increase the anticoagulant activities of Darexaban.Investigational
DeferasiroxThe risk or severity of adverse effects can be increased when Olsalazine is combined with Deferasirox.Approved, Investigational
DefibrotideThe risk or severity of adverse effects can be increased when Defibrotide is combined with Olsalazine.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Olsalazine is combined with Deflazacort.Approved, Investigational
DelaprilThe therapeutic efficacy of Delapril can be decreased when used in combination with Olsalazine.Experimental
DersalazineOlsalazine may increase the anticoagulant activities of Dersalazine.Investigational
DesipramineOlsalazine may decrease the antihypertensive activities of Desipramine.Approved, Investigational
DesirudinOlsalazine may increase the anticoagulant activities of Desirudin.Approved
DeslanosideThe serum concentration of Deslanoside can be decreased when it is combined with Olsalazine.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Olsalazine is combined with Desmopressin.Approved
DesmoteplaseThe risk or severity of adverse effects can be increased when Olsalazine is combined with Desmoteplase.Investigational
DesonideThe risk or severity of adverse effects can be increased when Olsalazine is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Olsalazine is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Olsalazine is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Olsalazine is combined with Dexamethasone isonicotinate.Vet Approved
DexibuprofenThe risk or severity of adverse effects can be increased when Olsalazine is combined with Dexibuprofen.Approved, Investigational
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Olsalazine.Approved, Investigational
DextranOlsalazine may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DibekacinOlsalazine may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
Dibotermin alfaThe risk or severity of adverse effects can be increased when Olsalazine is combined with Dibotermin alfa.Approved, Investigational
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Olsalazine.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Olsalazine is combined with Diclofenamide.Approved, Investigational
DicoumarolOlsalazine may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideDifenpiramide may increase the nephrotoxic activities of Olsalazine.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Olsalazine is combined with Diflunisal.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Olsalazine is combined with Difluprednate.Approved
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Olsalazine.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Olsalazine.Approved
Digoxin Immune Fab (Ovine)The serum concentration of Digoxin Immune Fab (Ovine) can be decreased when it is combined with Olsalazine.Approved
DihydrostreptomycinOlsalazine may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DiltiazemDiltiazem may increase the anticoagulant activities of Olsalazine.Approved, Investigational
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Olsalazine.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Olsalazine.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Olsalazine.Approved
DiphenadioneOlsalazine may increase the anticoagulant activities of Diphenadione.Experimental
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Olsalazine.Approved
DisopyramideOlsalazine may increase the hypoglycemic activities of Disopyramide.Approved
DitazoleThe risk or severity of adverse effects can be increased when Olsalazine is combined with Ditazole.Approved, Withdrawn
DorzolamideThe risk or severity of adverse effects can be increased when Olsalazine is combined with Dorzolamide.Approved
DrospirenoneOlsalazine may increase the hyperkalemic activities of Drospirenone.Approved
Drotrecogin alfaThe risk or severity of adverse effects can be increased when Olsalazine is combined with Drotrecogin alfa.Approved, Investigational, Withdrawn
DroxicamThe risk or severity of adverse effects can be increased when Olsalazine is combined with Droxicam.Withdrawn
DulaglutideOlsalazine may increase the hypoglycemic activities of Dulaglutide.Approved, Investigational
DuvelisibDuvelisib may increase the nephrotoxic activities of Olsalazine.Investigational
E-6201E-6201 may increase the nephrotoxic activities of Olsalazine.Investigational
Edetic AcidOlsalazine may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanOlsalazine may increase the anticoagulant activities of Edoxaban.Approved
EmpagliflozinOlsalazine may increase the hypoglycemic activities of Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Olsalazine is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Olsalazine is combined with Enalaprilat.Approved
EnoxacinOlsalazine may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinOlsalazine may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Olsalazine.Experimental
EpanololOlsalazine may decrease the antihypertensive activities of Epanolol.Experimental
EpinastineThe risk or severity of adverse effects can be increased when Epinastine is combined with Olsalazine.Approved, Investigational
EpirizoleEpirizole may increase the nephrotoxic activities of Olsalazine.Approved
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Olsalazine.Experimental
EplerenoneOlsalazine may decrease the antihypertensive activities of Eplerenone.Approved
EplivanserinThe risk or severity of adverse effects can be increased when Eplivanserin is combined with Olsalazine.Investigational
eplivanserineThe risk or severity of adverse effects can be increased when eplivanserine is combined with Olsalazine.Investigational
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Olsalazine.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Olsalazine.Approved
EptifibatideThe risk or severity of adverse effects can be increased when Eptifibatide is combined with Olsalazine.Approved, Investigational
EquileninThe risk or severity of adverse effects can be increased when Olsalazine is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Olsalazine is combined with Equilin.Approved
EsatenololOlsalazine may decrease the antihypertensive activities of Esatenolol.Experimental
EsmololOlsalazine may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Olsalazine is combined with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Olsalazine.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Olsalazine is combined with Etanercept.Approved, Investigational
EthenzamideEthenzamide may increase the nephrotoxic activities of Olsalazine.Experimental
EthoxzolamideThe risk or severity of adverse effects can be increased when Olsalazine is combined with Ethoxzolamide.Withdrawn
Ethyl biscoumacetateOlsalazine may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Olsalazine is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Olsalazine is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the nephrotoxic activities of Olsalazine.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Olsalazine is combined with Etoricoxib.Approved, Investigational
Evening primrose oilEvening primrose oil may increase the nephrotoxic activities of Olsalazine.Investigational, Nutraceutical
ExenatideOlsalazine may increase the hypoglycemic activities of Exenatide.Approved, Investigational
ExisulindExisulind may increase the nephrotoxic activities of Olsalazine.Investigational
FelbinacFelbinac may increase the nephrotoxic activities of Olsalazine.Experimental
FenbufenFenbufen may increase the nephrotoxic activities of Olsalazine.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Olsalazine is combined with Fenoprofen.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Olsalazine.Vet Approved
FentiazacFentiazac may increase the nephrotoxic activities of Olsalazine.Experimental
FeprazoneFeprazone may increase the nephrotoxic activities of Olsalazine.Experimental
Ferulic acidFerulic acid may increase the nephrotoxic activities of Olsalazine.Experimental
FibrinolysinThe risk or severity of adverse effects can be increased when Olsalazine is combined with Fibrinolysin.Investigational
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Olsalazine.Approved, Investigational
Fish oilThe risk or severity of adverse effects can be increased when Olsalazine is combined with Fish oil.Approved, Nutraceutical
FleroxacinOlsalazine may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Olsalazine.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Fludrocortisone.Approved, Investigational
FluindioneOlsalazine may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumequineOlsalazine may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Olsalazine is combined with Flunisolide.Approved, Investigational
FlunixinFlunixin may increase the nephrotoxic activities of Olsalazine.Vet Approved
FlunoxaprofenFlunoxaprofen may increase the nephrotoxic activities of Olsalazine.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Olsalazine is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Olsalazine is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Fluorometholone.Approved, Investigational
FluprednideneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Olsalazine.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Olsalazine is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Olsalazine is combined with Flurbiprofen.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Fluticasone.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Olsalazine is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Olsalazine is combined with Fluticasone propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Olsalazine.Approved, Nutraceutical, Vet Approved
FondaparinuxOlsalazine may increase the anticoagulant activities of Fondaparinux.Approved, Investigational
Fondaparinux sodiumOlsalazine may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Olsalazine.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Olsalazine is combined with Fosinopril.Approved
FramycetinOlsalazine may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Olsalazine.Approved, Vet Approved
GabexateOlsalazine may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinOlsalazine may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinOlsalazine may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Olsalazine.Approved, Withdrawn
GemifloxacinOlsalazine may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinOlsalazine may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinOlsalazine may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AOlsalazine may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
Ginkgo bilobaGinkgo biloba may increase the anticoagulant activities of Olsalazine.Approved, Investigational, Nutraceutical
GinsengThe risk or severity of adverse effects can be increased when Olsalazine is combined with Ginseng.Approved, Investigational, Nutraceutical
GitoformateThe serum concentration of Gitoformate can be decreased when it is combined with Olsalazine.Experimental
GliclazideOlsalazine may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideOlsalazine may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideOlsalazine may increase the hypoglycemic activities of Glipizide.Approved, Investigational
GlyburideOlsalazine may increase the hypoglycemic activities of Glyburide.Approved
GrepafloxacinOlsalazine may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalGuacetisal may increase the nephrotoxic activities of Olsalazine.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Olsalazine is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Olsalazine is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Olsalazine is combined with HE3286.Investigational
Hemoglobin crosfumarilOlsalazine may increase the anticoagulant activities of Hemoglobin crosfumaril.Experimental
HeparinThe risk or severity of adverse effects can be increased when Olsalazine is combined with Heparin.Approved, Investigational
HigenamineHigenamine may increase the nephrotoxic activities of Olsalazine.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Olsalazine.Approved, Investigational
HydralazineOlsalazine may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Olsalazine.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Olsalazine.Approved, Investigational
HydroxytyrosolThe risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Olsalazine.Investigational
Hygromycin BOlsalazine may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Olsalazine is combined with Ibandronate.Approved, Investigational
IbudilastThe risk or severity of adverse effects can be increased when Ibudilast is combined with Olsalazine.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Olsalazine is combined with Ibuprofen.Approved
IbuproxamIbuproxam may increase the nephrotoxic activities of Olsalazine.Withdrawn
IcatibantIcatibant may increase the nephrotoxic activities of Olsalazine.Approved, Investigational
IcosapentThe risk or severity of adverse effects can be increased when Olsalazine is combined with Icosapent.Approved, Nutraceutical
Icosapent ethylThe risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Olsalazine.Approved, Investigational, Nutraceutical
IdraparinuxOlsalazine may increase the anticoagulant activities of Idraparinux.Investigational
IfenprodilThe risk or severity of adverse effects can be increased when Ifenprodil is combined with Olsalazine.Approved, Investigational, Withdrawn
IfetrobanThe risk or severity of adverse effects can be increased when Ifetroban is combined with Olsalazine.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Olsalazine.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Olsalazine is combined with Imidapril.Investigational
Imidazole salicylateImidazole salicylate may increase the nephrotoxic activities of Olsalazine.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Olsalazine.Approved
IndenololOlsalazine may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Olsalazine is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Olsalazine is combined with Indomethacin.Approved, Investigational
IndoprofenIndoprofen may increase the nephrotoxic activities of Olsalazine.Withdrawn
Insulin AspartOlsalazine may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirOlsalazine may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineOlsalazine may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineOlsalazine may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanOlsalazine may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproOlsalazine may increase the hypoglycemic activities of Insulin Lispro.Approved
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Olsalazine.Approved, Investigational
IsepamicinOlsalazine may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamIsoxicam may increase the nephrotoxic activities of Olsalazine.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Olsalazine is combined with Istaroxime.Investigational
KanamycinOlsalazine may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneKebuzone may increase the nephrotoxic activities of Olsalazine.Experimental
KetanserinThe risk or severity of adverse effects can be increased when Ketanserin is combined with Olsalazine.Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Olsalazine is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Olsalazine.Approved
LabetalolOlsalazine may decrease the antihypertensive activities of Labetalol.Approved
Lanatoside CThe serum concentration of Lanatoside C can be decreased when it is combined with Olsalazine.Experimental
LandiololOlsalazine may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Olsalazine.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Olsalazine.Approved, Investigational
LeflunomideLeflunomide may increase the nephrotoxic activities of Olsalazine.Approved, Investigational
LepirudinOlsalazine may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanOlsalazine may increase the anticoagulant activities of Letaxaban.Investigational
LevobetaxololOlsalazine may decrease the antihypertensive activities of Levobetaxolol.Approved, Investigational
LevobunololOlsalazine may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinOlsalazine may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Olsalazine.Approved, Investigational
LinsidomineThe risk or severity of adverse effects can be increased when Linsidomine is combined with Olsalazine.Experimental
LiraglutideOlsalazine may increase the hypoglycemic activities of Liraglutide.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Olsalazine is combined with Lisinopril.Approved, Investigational
LisofyllineLisofylline may increase the nephrotoxic activities of Olsalazine.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Olsalazine.Approved
LomefloxacinOlsalazine may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
LonazolacLonazolac may increase the nephrotoxic activities of Olsalazine.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Olsalazine is combined with Lornoxicam.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Olsalazine.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Olsalazine is combined with Loteprednol.Approved
LoxoprofenLoxoprofen may increase the nephrotoxic activities of Olsalazine.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Olsalazine.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Olsalazine is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Olsalazine.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Olsalazine is combined with Magnesium salicylate.Approved
MasoprocolMasoprocol may increase the nephrotoxic activities of Olsalazine.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Olsalazine is combined with ME-609.Investigational
MecaserminOlsalazine may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Olsalazine is combined with Meclofenamic acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Olsalazine is combined with Mefenamic acid.Approved
MelagatranOlsalazine may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Olsalazine is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Olsalazine is combined with Meloxicam.Approved, Vet Approved
MepindololOlsalazine may decrease the antihypertensive activities of Mepindolol.Experimental
MercaptopurineThe metabolism of Mercaptopurine can be decreased when combined with Olsalazine.Approved
MesalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Mesalazine.Approved
MetamizoleMetamizole may increase the nephrotoxic activities of Olsalazine.Approved, Investigational, Withdrawn
MetforminOlsalazine may increase the hypoglycemic activities of Metformin.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Olsalazine is combined with Methazolamide.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Olsalazine.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Olsalazine.Approved
Methyl salicylateOlsalazine may increase the anticoagulant activities of Methyl salicylate.Approved, Vet Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Methylprednisolone.Approved, Vet Approved
MetildigoxinThe serum concentration of Metildigoxin can be decreased when it is combined with Olsalazine.Experimental
MetipranololOlsalazine may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Olsalazine.Approved
MetoprololOlsalazine may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MicronomicinOlsalazine may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Olsalazine.Approved, Experimental
MifepristoneOlsalazine may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolOlsalazine may increase the hypoglycemic activities of Miglitol.Approved
MilrinoneThe risk or severity of adverse effects can be increased when Milrinone is combined with Olsalazine.Approved
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Olsalazine.Approved
MizoribineMizoribine may increase the nephrotoxic activities of Olsalazine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Olsalazine is combined with Moexipril.Approved
MofebutazoneMofebutazone may increase the nephrotoxic activities of Olsalazine.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Olsalazine.Approved
MoxifloxacinOlsalazine may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilMycophenolate mofetil may increase the nephrotoxic activities of Olsalazine.Approved, Investigational
Mycophenolic acidMycophenolic acid may increase the nephrotoxic activities of Olsalazine.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Nabumetone.Approved
NadololOlsalazine may decrease the antihypertensive activities of Nadolol.Approved
NadroparinOlsalazine may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatNafamostat may increase the nephrotoxic activities of Olsalazine.Approved, Investigational
NaftifineNaftifine may increase the nephrotoxic activities of Olsalazine.Approved
NaftopidilThe risk or severity of adverse effects can be increased when Naftopidil is combined with Olsalazine.Investigational
Nalidixic AcidOlsalazine may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Olsalazine is combined with Naproxen.Approved, Vet Approved
NateglinideOlsalazine may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when Olsalazine is combined with NCX 1022.Investigational
NeamineOlsalazine may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololOlsalazine may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NemonoxacinOlsalazine may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinOlsalazine may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Olsalazine is combined with Nepafenac.Approved, Investigational
NetilmicinOlsalazine may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NifenazoneNifenazone may increase the nephrotoxic activities of Olsalazine.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Olsalazine is combined with Niflumic Acid.Approved
NimesulideThe risk or severity of adverse effects can be increased when Olsalazine is combined with Nimesulide.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Olsalazine.Investigational
NorfloxacinOlsalazine may increase the neuroexcitatory activities of Norfloxacin.Approved
OfloxacinOlsalazine may increase the neuroexcitatory activities of Ofloxacin.Approved
OleandrinThe serum concentration of Oleandrin can be decreased when it is combined with Olsalazine.Experimental, Investigational
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Olsalazine.Approved, Investigational
OlopatadineOlopatadine may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Olsalazine is combined with Omacetaxine mepesuccinate.Approved, Investigational
OmapatrilatThe risk or severity of adverse effects can be increased when Olsalazine is combined with Omapatrilat.Investigational
OrgoteinOrgotein may increase the nephrotoxic activities of Olsalazine.Vet Approved
OtamixabanOlsalazine may increase the anticoagulant activities of Otamixaban.Investigational
OuabainThe serum concentration of Ouabain can be decreased when it is combined with Olsalazine.Approved
OxaprozinThe risk or severity of adverse effects can be increased when Olsalazine is combined with Oxaprozin.Approved
Oxolinic acidOlsalazine may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololOlsalazine may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneOxyphenbutazone may increase the nephrotoxic activities of Olsalazine.Approved, Withdrawn
OzagrelThe risk or severity of adverse effects can be increased when Olsalazine is combined with Ozagrel.Investigational
PalmidrolPalmidrol may increase the nephrotoxic activities of Olsalazine.Experimental, Nutraceutical
PamidronateThe risk or severity of adverse effects can be increased when Olsalazine is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Olsalazine is combined with Parecoxib.Approved
ParnaparinThe risk or severity of adverse effects can be increased when Olsalazine is combined with Parnaparin.Approved, Investigational
ParomomycinOlsalazine may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideParthenolide may increase the nephrotoxic activities of Olsalazine.Approved, Investigational
PazufloxacinOlsalazine may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinOlsalazine may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololOlsalazine may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateOlsalazine may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
PentamidineOlsalazine may increase the hypoglycemic activities of Pentamidine.Approved, Investigational
Pentosan PolysulfateOlsalazine may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PentoxifyllineThe risk or severity of adverse effects can be increased when Pentoxifylline is combined with Olsalazine.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Olsalazine is combined with Perindopril.Approved
PeruvosideThe serum concentration of Peruvoside can be decreased when it is combined with Olsalazine.Experimental
PhenindioneOlsalazine may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonOlsalazine may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
Phenyl aminosalicylateOlsalazine may increase the anticoagulant activities of Phenyl aminosalicylate.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Phenylbutazone.Approved, Vet Approved
PicotamideThe risk or severity of adverse effects can be increased when Picotamide is combined with Olsalazine.Experimental
PimecrolimusPimecrolimus may increase the nephrotoxic activities of Olsalazine.Approved, Investigational
PindololOlsalazine may decrease the antihypertensive activities of Pindolol.Approved, Investigational
PioglitazoneOlsalazine may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
Pipemidic acidOlsalazine may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Olsalazine.Approved
PirfenidonePirfenidone may increase the nephrotoxic activities of Olsalazine.Approved, Investigational
Piromidic acidOlsalazine may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Olsalazine is combined with Piroxicam.Approved, Investigational
PirprofenPirprofen may increase the nephrotoxic activities of Olsalazine.Experimental
PitolisantThe risk or severity of adverse effects can be increased when Olsalazine is combined with Pitolisant.Approved, Investigational
Platelet Activating FactorOlsalazine may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinOlsalazine may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Olsalazine.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Olsalazine is combined with Pomalidomide.Approved
Potassium CitrateOlsalazine may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
PractololOlsalazine may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Olsalazine.Approved, Investigational
PramlintideOlsalazine may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PranoprofenPranoprofen may increase the nephrotoxic activities of Olsalazine.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Olsalazine is combined with Prasterone sulfate.Investigational
PrasugrelThe risk or severity of adverse effects can be increased when Prasugrel is combined with Olsalazine.Approved
PrednicarbateThe risk or severity of adverse effects can be increased when Olsalazine is combined with Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Pregnenolone.Approved, Experimental, Investigational
ProbenecidThe serum concentration of Olsalazine can be increased when it is combined with Probenecid.Approved, Investigational
ProglumetacinProglumetacin may increase the nephrotoxic activities of Olsalazine.Experimental
PropacetamolPropacetamol may increase the nephrotoxic activities of Olsalazine.Approved, Investigational
PropafenoneOlsalazine may decrease the antihypertensive activities of Propafenone.Approved
PropranololOlsalazine may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazonePropyphenazone may increase the nephrotoxic activities of Olsalazine.Experimental
ProquazoneProquazone may increase the nephrotoxic activities of Olsalazine.Experimental
ProscillaridinThe serum concentration of Proscillaridin can be decreased when it is combined with Olsalazine.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Olsalazine.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Olsalazine.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Olsalazine.Vet Approved
Protein COlsalazine may increase the anticoagulant activities of Protein C.Approved
Protein S humanOlsalazine may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeOlsalazine may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinOlsalazine may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299PTC299 may increase the nephrotoxic activities of Olsalazine.Investigational
PuromycinOlsalazine may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Olsalazine is combined with Quinapril.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Olsalazine.Approved
QuinineOlsalazine may increase the hypoglycemic activities of Quinine.Approved
RamatrobanThe risk or severity of adverse effects can be increased when Ramatroban is combined with Olsalazine.Investigational
RamiprilThe risk or severity of adverse effects can be increased when Olsalazine is combined with Ramipril.Approved
RelcovaptanThe risk or severity of adverse effects can be increased when Relcovaptan is combined with Olsalazine.Investigational
RepaglinideOlsalazine may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RescinnamineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Rescinnamine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Olsalazine is combined with Resveratrol.Approved, Experimental, Investigational
ReteplaseThe risk or severity of adverse effects can be increased when Olsalazine is combined with Reteplase.Approved, Investigational
ReviparinOlsalazine may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinOlsalazine may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RidogrelThe risk or severity of adverse effects can be increased when Ridogrel is combined with Olsalazine.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Olsalazine is combined with Risedronate.Approved, Investigational
RivaroxabanOlsalazine may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Olsalazine is combined with Rofecoxib.Approved, Investigational, Withdrawn
RosiglitazoneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Rosiglitazone.Approved, Investigational
RosoxacinOlsalazine may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RufloxacinOlsalazine may increase the neuroexcitatory activities of Rufloxacin.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Olsalazine.Approved
SalicylamideSalicylamide may increase the nephrotoxic activities of Olsalazine.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Olsalazine is combined with Salicylic acid.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Olsalazine is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Olsalazine.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Olsalazine.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Olsalazine.Approved, Investigational
SarpogrelateThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Olsalazine.Investigational
SaruplaseThe risk or severity of adverse effects can be increased when Olsalazine is combined with Saruplase.Experimental
SaxagliptinOlsalazine may increase the hypoglycemic activities of Saxagliptin.Approved
SelexipagThe risk or severity of adverse effects can be increased when Olsalazine is combined with Selexipag.Approved
SeliciclibThe risk or severity of adverse effects can be increased when Olsalazine is combined with Seliciclib.Investigational
SemapimodSemapimod may increase the nephrotoxic activities of Olsalazine.Investigational
SeratrodastSeratrodast may increase the nephrotoxic activities of Olsalazine.Approved
SerrapeptaseSerrapeptase may increase the nephrotoxic activities of Olsalazine.Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Olsalazine.Approved, Vet Approved
SisomicinOlsalazine may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinOlsalazine may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
SitagliptinOlsalazine may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
Sodium CitrateOlsalazine may increase the anticoagulant activities of Sodium Citrate.Approved, Investigational
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Olsalazine.Approved
SotalolOlsalazine may decrease the antihypertensive activities of Sotalol.Approved
SparfloxacinOlsalazine may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpiraprilThe risk or severity of adverse effects can be increased when Olsalazine is combined with Spirapril.Approved
SpironolactoneOlsalazine may decrease the antihypertensive activities of Spironolactone.Approved
SRT501SRT501 may increase the nephrotoxic activities of Olsalazine.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Olsalazine is combined with Streptokinase.Approved, Investigational
StreptomycinOlsalazine may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
SulfadiazineOlsalazine may increase the hypoglycemic activities of Sulfadiazine.Approved, Investigational, Vet Approved
SulfamethoxazoleOlsalazine may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Sulfasalazine.Approved
SulfisoxazoleOlsalazine may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Olsalazine is combined with Sulindac.Approved, Investigational
SulodexideOlsalazine may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Olsalazine.Investigational
SunitinibOlsalazine may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Olsalazine is combined with Suprofen.Approved, Withdrawn
SuxibuzoneSuxibuzone may increase the nephrotoxic activities of Olsalazine.Experimental
TacrolimusOlsalazine may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Olsalazine.Approved
TalinololOlsalazine may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Olsalazine.Approved
TarenflurbilTarenflurbil may increase the nephrotoxic activities of Olsalazine.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Olsalazine.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Olsalazine is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Olsalazine is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Olsalazine.Approved, Investigational
TemafloxacinOlsalazine may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Olsalazine is combined with Temocapril.Experimental, Investigational
TenecteplaseThe risk or severity of adverse effects can be increased when Olsalazine is combined with Tenecteplase.Approved
TenidapTenidap may increase the nephrotoxic activities of Olsalazine.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Olsalazine is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Olsalazine is combined with Tenoxicam.Approved
TepoxalinTepoxalin may increase the nephrotoxic activities of Olsalazine.Vet Approved
TerbutalineOlsalazine may decrease the antihypertensive activities of Terbutaline.Approved
TeriflunomideTeriflunomide may increase the nephrotoxic activities of Olsalazine.Approved
TertatololOlsalazine may decrease the antihypertensive activities of Tertatolol.Experimental
TesmilifeneThe risk or severity of adverse effects can be increased when Tesmilifene is combined with Olsalazine.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Olsalazine is combined with Tiaprofenic acid.Approved
TicagrelorThe risk or severity of adverse effects can be increased when Olsalazine is combined with Ticagrelor.Approved
TiclopidineThe risk or severity of adverse effects can be increased when Ticlopidine is combined with Olsalazine.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Olsalazine is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololOlsalazine may decrease the antihypertensive activities of Timolol.Approved
TinoridineTinoridine may increase the nephrotoxic activities of Olsalazine.Investigational
TinzaparinThe risk or severity of adverse effects can be increased when Olsalazine is combined with Tinzaparin.Approved
TioclomarolOlsalazine may increase the anticoagulant activities of Tioclomarol.Experimental
TioguanineThe metabolism of Tioguanine can be decreased when combined with Olsalazine.Approved
TirofibanThe risk or severity of adverse effects can be increased when Tirofiban is combined with Olsalazine.Approved
TixocortolThe risk or severity of adverse effects can be increased when Olsalazine is combined with Tixocortol.Approved, Withdrawn
TobramycinOlsalazine may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TolazamideOlsalazine may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
TolbutamideOlsalazine may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
Tolfenamic AcidTolfenamic Acid may increase the nephrotoxic activities of Olsalazine.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Olsalazine is combined with Tolmetin.Approved
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Olsalazine.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Olsalazine is combined with Trandolapril.Approved
TranilastTranilast may increase the nephrotoxic activities of Olsalazine.Approved, Investigational
TrapidilThe risk or severity of adverse effects can be increased when Trapidil is combined with Olsalazine.Approved
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Olsalazine.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Olsalazine.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Olsalazine is combined with Triamcinolone.Approved, Vet Approved
TriamtereneOlsalazine may decrease the antihypertensive activities of Triamterene.Approved
TribenosideTribenoside may increase the nephrotoxic activities of Olsalazine.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Olsalazine.Approved, Vet Approved
TriflusalThe risk or severity of adverse effects can be increased when Triflusal is combined with Olsalazine.Approved, Investigational
TriptolideTriptolide may increase the nephrotoxic activities of Olsalazine.Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Olsalazine is combined with Trolamine salicylate.Approved
TrovafloxacinOlsalazine may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinOlsalazine may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Olsalazine is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Olsalazine.Approved, Investigational
UrokinaseThe risk or severity of adverse effects can be increased when Olsalazine is combined with Urokinase.Approved, Investigational, Withdrawn
ValdecoxibThe risk or severity of adverse effects can be increased when Olsalazine is combined with Valdecoxib.Approved, Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be increased when it is combined with Olsalazine.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Olsalazine.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Olsalazine.Approved
VerapamilVerapamil may increase the anticoagulant activities of Olsalazine.Approved
VorapaxarThe risk or severity of adverse effects can be increased when Vorapaxar is combined with Olsalazine.Approved
WarfarinOlsalazine may increase the anticoagulant activities of Warfarin.Approved
XimelagatranOlsalazine may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenZaltoprofen may increase the nephrotoxic activities of Olsalazine.Approved, Investigational
ZileutonZileuton may increase the nephrotoxic activities of Olsalazine.Approved, Investigational, Withdrawn
ZofenoprilThe therapeutic efficacy of Zofenopril can be decreased when used in combination with Olsalazine.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Olsalazine is combined with Zoledronic acid.Approved
ZomepiracZomepirac may increase the nephrotoxic activities of Olsalazine.Withdrawn
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB0015380
KEGG Drug
D00727
KEGG Compound
C07323
PubChem Compound
6003770
PubChem Substance
46506356
ChemSpider
10642377
ChEMBL
CHEMBL425
PharmGKB
PA450700
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Olsalazine
ATC Codes
A07EC03 — Olsalazine
AHFS Codes
  • 56:36.00 — Anti-inflammatory Agents

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentAnkylosing Spondylitis (AS)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Alaven Pharmaceutical
  • Pfizer Inc.
  • Pharmacia Inc.
  • UCB Pharma
Dosage forms
FormRouteStrength
CapsuleOral250 mg
Capsule, gelatin coatedOral250 mg/1
Prices
Unit descriptionCostUnit
Dipentum 250 mg capsule1.8USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)Sodium salt decomposes at 240 °CNot Available
logP2.3Not Available
Caco2 permeability-6.96ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.0781 mg/mLALOGPS
logP2.77ALOGPS
logP4.39ChemAxon
logS-3.6ALOGPS
pKa (Strongest Acidic)2.93ChemAxon
pKa (Strongest Basic)-0.019ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area139.78 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity78.85 m3·mol-1ChemAxon
Polarizability28.61 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8502
Blood Brain Barrier+0.6279
Caco-2 permeable-0.6449
P-glycoprotein substrateNon-substrate0.7433
P-glycoprotein inhibitor INon-inhibitor0.8628
P-glycoprotein inhibitor IINon-inhibitor0.9525
Renal organic cation transporterNon-inhibitor0.8844
CYP450 2C9 substrateNon-substrate0.7774
CYP450 2D6 substrateNon-substrate0.8748
CYP450 3A4 substrateNon-substrate0.6636
CYP450 1A2 substrateNon-inhibitor0.8006
CYP450 2C9 inhibitorNon-inhibitor0.7804
CYP450 2D6 inhibitorNon-inhibitor0.9047
CYP450 2C19 inhibitorNon-inhibitor0.8638
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8912
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.5546
BiodegradationNot ready biodegradable0.8701
Rat acute toxicity1.4882 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9506
hERG inhibition (predictor II)Non-inhibitor0.9453
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as azobenzenes. These are organonitrogen aromatic compounds that contain a central azo group, where each nitrogen atom is conjugated to a benzene ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Azobenzenes
Sub Class
Not Available
Direct Parent
Azobenzenes
Alternative Parents
Salicylic acids / Benzoic acids / Benzoyl derivatives / 1-hydroxy-2-unsubstituted benzenoids / Dicarboxylic acids and derivatives / Vinylogous acids / Azo compounds / Propargyl-type 1,3-dipolar organic compounds / Carboxylic acids / Organopnictogen compounds
show 3 more
Substituents
Azobenzene / Hydroxybenzoic acid / Salicylic acid or derivatives / Salicylic acid / Benzoic acid or derivatives / Benzoic acid / Benzoyl / 1-hydroxy-2-unsubstituted benzenoid / Phenol / Monocyclic benzene moiety
show 16 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Thiopurine s-methyltransferase activity
Specific Function
Catalyzes the S-methylation of thiopurine drugs such as 6-mercaptopurine.
Gene Name
TPMT
Uniprot ID
P51580
Uniprot Name
Thiopurine S-methyltransferase
Molecular Weight
28180.09 Da
References
  1. Lewis LD, Benin A, Szumlanski CL, Otterness DM, Lennard L, Weinshilboum RM, Nierenberg DW: Olsalazine and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interaction. Clin Pharmacol Ther. 1997 Oct;62(4):464-75. [PubMed:9357398]
  2. Lennard L: TPMT in the treatment of Crohn's disease with azathioprine. Gut. 2002 Aug;51(2):143-6. [PubMed:12117866]
  3. Lennard L: Clinical implications of thiopurine methyltransferase--optimization of drug dosage and potential drug interactions. Ther Drug Monit. 1998 Oct;20(5):527-31. [PubMed:9780130]
  4. Shipkova M, Niedmann PD, Armstrong VW, Oellerich M, Wieland E: Determination of thiopurine methyltransferase activity in isolated human erythrocytes does not reflect putative in vivo enzyme inhibition by sulfasalazine. Clin Chem. 2004 Feb;50(2):438-41. [PubMed:14752016]
Kind
Protein
Organism
Human
Pharmacological action
Yes
General Function
Interferon-gamma receptor binding
Specific Function
Produced by lymphocytes activated by specific antigens or mitogens. IFN-gamma, in addition to having antiviral activity, has important immunoregulatory functions. It is a potent activator of macrop...
Gene Name
IFNG
Uniprot ID
P01579
Uniprot Name
Interferon gamma
Molecular Weight
19348.165 Da
References
  1. Egan LJ, Sandborn WJ: Inhibition of nuclear factor kappaB by sulfasalazine: a new target for inflammatory bowel disease therapy? Gastroenterology. 1998 Nov;115(5):1295-6. [PubMed:9797390]
  2. Ito R, Shin-Ya M, Kishida T, Urano A, Takada R, Sakagami J, Imanishi J, Kita M, Ueda Y, Iwakura Y, Kataoka K, Okanoue T, Mazda O: Interferon-gamma is causatively involved in experimental inflammatory bowel disease in mice. Clin Exp Immunol. 2006 Nov;146(2):330-8. [PubMed:17034586]

Drug created on March 30, 2007 06:25 / Updated on June 16, 2018 22:12